Na+/K+-ATPase α3 mediates sensitivity of hepatocellular carcinoma cells to bufalin

Oncology Reports

Volumn 25, Issue 3, 2011, Pages 825-830

  Li, Huaxing ^a   Wang, Peng ^a   Gao, Yang ^a   Zhu, Xiaoyan ^a   Liu, Luming ^a   Cohen, Lorenzo ^b   Meng, Zhiqiang ^a   Yang, Peiying ^c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Bufalin; Hepatocellular carcinoma; Na+ K+ ATPase 3

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) ALPHA3; BUFALIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; IC 50; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; BUFANOLIDES; CARCINOMA, HEPATOCELLULAR; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; PROGNOSIS; RNA, SMALL INTERFERING; SODIUM-POTASSIUM-EXCHANGING ATPASE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 79551607782     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2010.1120     Document Type: Article

References (33)

1. Watabe M, Kawazoe N, Masuda Y, Nakajo S and Nakaya K: Bcl-2 protein inhibits bufalin-induced apoptosis through inhibition of mitogen-activated protein kinase activation in human leukemia U937 cells. Cancer Res 57: 3097-3100, 1997.
2. Watabe M, Ito K, Masuda Y, Nakajo S and Nakaya K: Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene 16: 779-787, 1998.
3. Kawazoe N, Watabe M, Masuda Y, Nakajo S and Nakaya K: Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells. Oncogene 18: 2413-2421, 1999.
4. Yeh JY, Huang WJ, Kan SF and Wang PS: Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 54: 112-124, 2003.
5. Han KQ, Huang G, Gu W, Su YH, Huang XQ and Ling CQ: Anti-tumor activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumor model of human hepatocellular carcinoma in nude mice. World J Gastroenterol 13: 3374-3379, 2007.
6. Yin JQ, Shen JN, Su WW, Wang J, Huang G, Jin S, Guo QC, Zou CY, Li HM and Li FB: Bufalin induces apoptosis in human osteosarcoma U-2OS and U-2OS methotrexate300-resistant cell lines. Acta Pharmacol Sin 28: 712-720, 2007.
7. Newman RA, Yang P, Pawlus AD and Block KI: Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 8: 36-49, 2008.
8. +-ATPase to growth-related genes in cardiac myocytes. The roles of Ras and mitogen-activated protein kinases. J Biol Chem 273: 15249-15256, 1998.
9. Espineda C, Seligson DB, James Ball W Jr, Rao J, Palotie A, Horvath S, Huang Y, Shi T and Rajasekaran AK: Analysis of the Na,K-ATPase alpha- and beta-subunit expression profiles of bladder cancer using tissue microarrays. Cancer 97: 1859-1868, 2003.
10. Sakai H, Suzuki T, Maeda M, Takahashi Y, Horikawa N, Minamimura T, Tsukada K and Takeguchi N: Up-regulation of Na(+),K(+)-ATPase alpha 3-isoform and down-regulation of the alpha1-isoform in human colorectal cancer. FEBS Lett 563: 151-154, 2004.
11. Rajasekaran SA, Ball WJ Jr, Bander NH, Liu H, Pardee JD and Rajasekaran AK: Reduced expression of beta-subunit of Na,K-ATPase in human clear-cell renal cell carcinoma. J Urol 162: 574-580, 1999.
12. Akopyanz NS, Broude NE, Bekman EP, Marzen EO and Sverdlov ED: Tissue-specific expression of Na,K-ATPase beta-subunit. Does beta 2 expression correlate with tumorigenesis? FEBS Lett 289: 8-10, 1991.
13. Yang P, Menter DG, Cartwright C, Chan D, Dixon S, Suraokar M, Mendoza G, Llansa N and Newman RA: Oleandrin-mediated inhibition of human tumor cell proliferation: importance of Na,K-ATPase alpha subunits as drug targets. Mol Cancer Ther 8: 2319-2328, 2009.
14. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
15. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
16. Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, Newman RA, Cohen L, Liu L, Thornton B, Chang DZ, Liao Z and Kurzrock R: Pilot study of huachansu in patients with hepatocellular carcinoma, non-small-cell lung cancer, or pancreatic cancer. Cancer 115: 5309-5318, 2009.
17. Lekanne Deprez RH, Fijnvandraat AC, Ruijter JM and Moorman AF: Sensitivity and accuracy of quantitative real-time polymerase chain reaction using SYBR green I depends on cDNA synthesis conditions. Anal Biochem 307: 63-69, 2002.
18. Wang P, Chen Z, Meng ZQ, Fan J, Luo JM, Liang W, Lin JH, Zhou ZH, Chen H, Wang K, Shen YH, Xu ZD and Liu LM: Dual role of Ski in pancreatic cancer cells: tumor-promoting versus metastasis-suppressive function. Carcinogenesis 30: 1497-1506, 2009.
19. Stenkvist B: Cardenolides and cancer. Anticancer Drugs 12: 635-638, 2001.
20. Mijatovic T, Roland I, Van Quaquebeke E, Nilsson B, Mathieu A, Van Vynckt F, Darro F, Blanco G, Facchini V and Kiss R: The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J Pathol 212: 170-179, 2007.
21. Kaplan JH: Biochemistry of Na,K-ATPase. Annu Rev Biochem 71: 511-535, 2002.
22. Aydemir-Koksoy A, Abramowitz J and Allen JC: Ouabain-induced signaling and vascular smooth muscle cell proliferation. J Biol Chem 276: 46605-46611, 2001.
23. +-ATPase. J Biol Chem 275: 27832-27837, 2000.
24. +-ATPase and the epidermal growth factor receptor relays the signal from ouabain to mitogen-activated protein kinases. J Biol Chem 277: 18694-18702, 2002.
25. Yoeli-Lerner M and Toker A: Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle 5: 603-605, 2006.
26. Gonzalez E and McGraw TE: The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 8: 2502-2508, 2009.
27. Plas DR and Thompson CB: Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24: 7435-7442, 2005.
28. Robey RB and Hay N: Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt. Oncogene 25: 4683-4696, 2006.
29. Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, Unterman T and Hay N: Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 14: 458-470, 2008.
30. Garcia-Echeverria C and Sellers WR: Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27: 5511-5526, 2008.
31. Navarro R, Busnadiego I, Ruiz-Larrea MB and Ruiz-Sanz JI: Superoxide anions are involved in doxorubicin-induced ERK activation in hepatocyte cultures. Ann N Y Acad Sci 1090: 419-428, 2006.
32. Matsuzawa A and Ichijo H: Stress-responsive protein kinases in redox-regulated apoptosis signaling. Antioxid Redox Signal 7: 4724-4781, 2005.
33. Dhillon AS, Hagan S, Rath O and Kolch W: MAP kinase signalling pathways in cancer. Oncogene 26: 3279-3290, 2007.